Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact

References

• Martin P, Leighl NB, Tsao MS, et al. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol. 2013;8(5):530–542.
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287–1292.
   PubMed Web of Science ®Google Scholar
• Aredo JV, Padda SK, Kunder CA, et al. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer. 2019;133:144–150.
   PubMed Web of Science ®Google Scholar
• Scheffler M, Ihle MA, Hein R, et al. K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways. J Thorac Oncol. 2019;14(4):606–616.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529–3545.
   PubMed Web of Science ®Google Scholar
• Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol. 2013;5(5):97–101.
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Koustas E, Goulielmaki M, et al. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget. 2014;5(23):11752–11777.
   PubMed Web of Science ®Google Scholar
• Haigis KM. KRAS alleles: the devil is in the detail. Trends Cancer. 2017;3(10):686–697.
   PubMed Web of Science ®Google Scholar
• Dunnett-Kane V, Nicola P, Blackhall F, et al. Mechanisms of resistance to KRASG12C inhibitors. Cancers. 2021;13(1):151.
   PubMed Web of Science ®Google Scholar
• Mustachio LM, Chelariu-Raicu A, Szekvolgyi L, et al. Targeting KRAS in cancer: promising therapeutic strategies. Cancers. 2021;13(6):1204.
   PubMed Web of Science ®Google Scholar
• Sahin IH, Garrett CR. Predicting cetuximab efficacy in patients with advanced colorectal cancer. Curr Biomark Find. 2014;4:61–68.
   Google Scholar
• Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):e17.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Hainsworth J, Bose R, et al. MyPathway HER2 basket study: pertuzumab (P)+trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. J Clin Oncol. 2021;39(15_Suppl):3004–3004.
   Web of Science ®Google Scholar
• Tuxen IV, Jønson L, Santoni-Rugiu E, et al. Personalized oncology: genomic screening in phase 1. APMIS. 2014;122(8):723–733.
   PubMed Web of Science ®Google Scholar
• Tuxen IV, Rohrberg KS, Oestrup O, et al. Copenhagen prospective personalized oncology (CoPPO)—clinical utility of using molecular profiling to select patients to phase I trials. Clin Cancer Res. 2019;25(4):1239–1247.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software partners. J Biomed Inform. 2019;95:103208.
   PubMed Web of Science ®Google Scholar
• Tuxen IV, Ahlborn LB, Mau-Soerensen M, et al. Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients. Br J Cancer. 2019;121(2):125–130.
   PubMed Web of Science ®Google Scholar
• Szustakowski J, Green G, Geese WJ, et al. Evaluation of tumor mutational burden as a biomarker for immune checkpoint inhibitor efficacy: a calibration study of whole exome sequencing with FoundationOne. Cancer Res. 2018;78(13_Suppl):5528–5528.
   Web of Science ®Google Scholar
• Marquard AM, Eklund AC, Joshi T, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3:9.
   PubMedGoogle Scholar
• RStudio Team. RStudio: integrated development for R. Boston (MA): RStudio, PBC; 2020.
   Google Scholar
• IBM Corp. IBM SPSS statistics for windows, version 25.0. Armonk (NY): IBM Corp; 2017.
   Google Scholar
• Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev. 2020;39(4):1029–1038.
   PubMed Web of Science ®Google Scholar
• Zhou J, Fan X, Chen N, et al. Identification of CEACAM5 as a biomarker for prewarning and prognosis in gastric cancer. J Histochem Cytochem. 2015;63(12):922–930.
   PubMed Web of Science ®Google Scholar
• Slattery ML, Curtin K, Wolff RK, et al. A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum. 2009;52(7):1304–1311.
   PubMed Web of Science ®Google Scholar
• Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356–86368.
   PubMedGoogle Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.
   PubMed Web of Science ®Google Scholar
• AACR Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818–831.
   PubMed Web of Science ®Google Scholar
• Del Re M, Rofi E, Restante G, et al. Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget. 2018;9(5):6630–6643.
   PubMedGoogle Scholar
• Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51(18):2792–2799.
   PubMed Web of Science ®Google Scholar
• Niemantsverdriet M, Schuuring E, ter Elst A, et al. KRAS mutation as a resistance mechanism to BRAF/MEK inhibition in NSCLC. J Thorac Oncol. 2018;13(12):249–251.
   Web of Science ®Google Scholar
• Jones RP, Sutton PA, Evans JP, et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116(7):923–929.
   PubMed Web of Science ®Google Scholar
• Kulemann B, Rösch S, Seifert S, et al. Pancreatic cancer: circulating tumor cells and primary tumors show heterogeneous KRAS mutations. Sci Rep. 2017;7(1):4510.
   PubMedGoogle Scholar
• La Fleur L, Falk-Sörqvist E, Smeds P, et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 2019;130:50–58.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822–835.
   PubMed Web of Science ®Google Scholar
• Riely G, Ou SI, Rybkin I, et al. KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thorac Oncol. 2021;16:S748–S802.
   Web of Science ®Google Scholar
• Johnson ML, Ou SHI, Barve M, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer and other solid tumors harboring a KRAS G12C mutation. 2020 EORTC-NCI-AACR Symposium (abstr LBA4).
   Google Scholar
• Janne PA, Rybkin II, Spira AI, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in advanced/metastatic non-small-cell lung cancer harboring KRAS G12C mutation. 2020 EORTC-NCI-AACR Symposium (abstr LBA3).
   Google Scholar
• Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–1217.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Kesselheim AS. The promise of ESCAT: a new system for evaluating cancer drug-target pairs. Nat Rev Clin Oncol. 2019;16(3):147–148.
   PubMed Web of Science ®Google Scholar